Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma

被引：0
|
作者：
Albrecht, L. J. [1 ]
Dimitriou, F. [2 ]
Grover, P. [3 ]
Hassel, J. C. [4 ,5 ]
Erdmann, M. [6 ]
Forschner, A. [7 ]
Johnson, D. [8 ,9 ]
Livingstone, E. [1 ]
Roesch, A. [1 ,10 ]
Ugurel, S. [1 ]
Schulz, C. [4 ,5 ]
Berking, C. [6 ]
Menzies, A. M. [3 ,11 ,12 ]
Long, G. V. [11 ,12 ]
Dummer, R. [2 ]
Schadendorf, D. [1 ,10 ]
Zimmer, L. [1 ]
机构：
[1] Univ Hosp Essen, Dept Dermatol, Essen, Germany
[2] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland
[3] Univ Sydney, Melanoma Inst Australia, Sydney, Australia
[4] Univ Hosp Heidelberg, Dept Dermatol, Heidelberg, Germany
[5] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[6] Univ Hosp Erlangen, Dept Dermatol, Erlangen, Germany
[7] Univ Hosp Tuebingen, Dept Dermatol, Tubingen, Germany
[8] VUMC, Dept Med, Div Hematol & Oncol, Nashville, TN USA
[9] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN USA
[10] German Canc Consortium DKTK, Essen, Germany
[11] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, Australia
[12] Univ Sydney, Fac Med & Hlth, Sydney, Australia
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP023
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [41] Cardiovascular monitoring in metastatic melanoma patients undergoing combination therapy with BRAF and MEK inhibitors
    Guglielmi, Giulia
    Sarocchi, Matteo
    Tini, Giacomo
    Schiavone, Arianna
    Toma, Matteo
    Spagnolo, Francesco
    Tanda, Enrica Teresa
    Boutros, Andrea
    Spallarossa, Paolo
    Porto, Italo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N20 - N21
  • [42] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Babacan, Nalan Akgul
    Eroglu, Zeynep
    CURRENT ONCOLOGY REPORTS, 2020, 22 (04)
  • [43] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Nalan Akgul Babacan
    Zeynep Eroglu
    Current Oncology Reports, 2020, 22
  • [44] Clinical analysis of patients (pts) with lung cancer treated with anti-PD1/PDL1 therapy
    Zhao, Xin
    Liu, Siyao
    Su, Junyan
    CANCER RESEARCH, 2023, 83 (07)
  • [45] Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases
    Fujisawa, Yasuhiro
    Ito, Takamichi
    Kato, Hiroshi
    Irie, Hiroyuki
    Kaji, Tatsuya
    Maekawa, Takeo
    Asai, Jun
    Yamamoto, Yuki
    Fujimura, Taku
    Nakai, Yasuo
    Yasuda, Masahito
    Matsuyama, Kanako
    Muto, Ikko
    Matsushita, Shigeto
    Uchi, Hiroshi
    Nakamura, Yoshiyuki
    Uehara, Jiro
    Yoshino, Koji
    EUROPEAN JOURNAL OF CANCER, 2021, 145 : 210 - 220
  • [46] Toxicity and Survival for Metastatic Melanoma Patients Treated With Anti-PD1 Therapy and Radiation Treatment
    Mowery, Y. M.
    Patel, K.
    Olson, A. C.
    Khan, M. K.
    Salama, J. K.
    Salama, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S158 - S159
  • [47] Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.
    Eroglu, Zeynep
    Kim, Dae Won
    Johnson, Douglas Buckner
    Algazi, Alain Patrick
    Munhoz, Rodrigo Ramella
    Liniker, Elizabeth
    Kong, Ben
    Khurana, Neharika
    Chmielowski, Bartosz
    Sosman, Jeffrey Alan
    Scolyer, Richard A.
    Carlino, Matteo S.
    Postow, Michael Andrew
    Hwu, Wen-Jen
    Long, Georgina V.
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Neutrophil subset investigation in stage III melanoma patients undergoing anti-PD-1 immunotherapy or anti-BRAF/MEK target therapy
    Trocchia, Marialuisa
    Cristinziano, Leonardo
    Modestino, Luca
    Ventrici, Annagioia
    Loffredo, Stefania
    Ferrara, Anne Lise
    Tocchetti, Carlo Gabriele
    Troiani, Teresa
    Marone, Gianni
    Galdiero, Maria Rosaria
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 1105 - 1105
  • [49] Results of a study of horvermogens in patients with malignant melanoma before, during or after systemic therapy with checkpoint inhibitors or BRAF and MEK inhibitors
    Ehrmann, J.
    Wenzel, G. I.
    Vogt, T.
    Pfoehler, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 129 - 129
  • [50] Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
    De Meza, Melissa M. M.
    Blokx, Willeke A. M.
    Bonenkamp, Johannes J. J.
    Blank, Christian U. U.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    Boers-Sonderen, Marye J. J.
    De Groot, Jan Willem B.
    Haanen, John B. A. G.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Van Not, Olivier J. J.
    Piersma, Djura
    Van Rijn, Rozemarijn S. S.
    Stevense-den Boer, Marion
    van der Veldt, Astrid A. M.
    Vreugdenhil, Gerard
    van den Eertwegh, Alfonsus J. M.
    Suijkerbuijk, Karijn P. M.
    Wouters, Michel W. J. M.
    CANCERS, 2023, 15 (02)
12345